イスラエル, テルアビブ
- アリ・ラファエル医師は臨床研究に多大な貢献をしており、患者の臨床試験への参加促進に尽力しています。
- スラスキー医療センター(イキロフ)は年間40万人以上の患者を診療しており、医療渡航者にとって上位10施設の一つです。
- 費用に含まれるもの:入院、病院への送迎。
- 滞在情報:入院1日、ホテル滞在1日。
- 治療法:HER2陽性早期乳癌またはHER2陽性転移性乳癌に対するKADCYLA療法。
| イスラエル | トルコ | オーストリア | |
| 分子標的治療 | から $9,500 | から $1,000 | から $12,000 |
| ルテチウム177療法 | から $16,500 | から $8,800 | から $35,000 |
| 温熱療法 | - | から $450 | - |
| アクチニウム225療法 | - | から $22,955 | から $55,000 |
Bookimedは分子標的治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで分子標的治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。分子標的治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。分子標的治療の旅路でお一人になることはありません。
ペレス・シャロン医師は、ソウラスキー医療センターにおいて、分子標的療法およびその他の高度ながん治療に豊富な経験を持つ、高く評価されている腫瘍専門医です。
オフェル・メリムスキー教授は、ソウラスキー医療センターの軟部組織・骨腫瘍科を率いており、イスラエルを代表する肉腫専門医です。
この医師は化学療法と放射線療法の専門家であり、乳がん、子宮がん、前立腺がん、消化管がん、肺がん、腎臓がん、膀胱がんを含む様々な腫瘍性疾患の治療に焦点を当てています。医師は化学療法、放射線療法、生物学的がん治療などの先進的な治療法を用い、がん治療後のリハビリテーションも提供しています。
1988年からの経験を持ち、2009年からSourasky (Ichilov) Medical Centerで上級腫瘍専門医として勤務しており、Rambam Medical CenterおよびSourasky Medical Centerで重要な役職を歴任しています。医師は30以上の科学論文に貢献しており、がん治療の臨床試験にも関与しています。
Choosing the best targeted therapy doctor in Israel requires identifying specialists with international fellowship training and clinical trial leadership. Prioritize board-certified oncologists at JCI-accredited centers like Sourasky Medical Center. These experts often hold memberships in the European Society of Medical Oncology (ESMO).
Bookimed Expert Insight: Data shows that choosing a doctor who moderates a Molecular Tumor Board, such as Dr. Ari Raphael, provides a significant advantage. These specialists don't just prescribe standard drugs but specialize in NGS interpretation. This ensures that targeted therapies are matched to specific genetic mutations rather than just the cancer type.
Patient Consensus: Patients note that working with doctors who run clinical trials often provides access to new protocols. They emphasize choosing specialists in Tel Aviv who participate in multidisciplinary boards for better-tailored treatments. Many felt more confident when their doctor had published research on their specific biomarker.
Israeli oncologists lead targeted therapy through rapid clinical translation of genomic research and unique diagnostic accuracy. Specialists like Dr. Ari Raphael and Prof. Ofer Merimsky integrate advanced liquid biopsies and molecular profiling into routine care. This precision approach often corrects initial diagnoses for up to 91% of complex international cases.
Bookimed Expert Insight: A distinct advantage in Israel is the integration of genomic medicine into national health initiatives. Dr. Ari Raphael leads the National Genomic Medicine Initiative, which allows for earlier access to T-cell sequencing and cfDNA monitoring. This structural collaboration means patients at clinics like Sourasky Medical Center receive experimental protocols years before they reach global markets.
Patient Consensus: Patients often mention being surprised by the depth of genomic testing available compared to their home countries. Many note that the innovative approach to rare mutations gave them treatment options they were previously told did not exist. They describe feeling a sense of relief when specialized protocols were tailored specifically to their genetic markers.
You can receive a second opinion from leading targeted therapy specialists in Israel through remote video consultations or in-person visits. Top oncologists at JCI-accredited centers like Sourasky Medical Center (Ichilov) and Assuta Medical Center provide genomic-guided treatment plans and access to early-phase clinical trials.
Bookimed Expert Insight: Israeli oncology centers often provide faster access to rare mutation analysis compared to many European facilities. Data shows that specialists like Dr. Ari Raphael at Sourasky Medical Center (Ichilov) integrate computational biology with clinical trials. This allows patients to receive personalized therapy recommendations based on the latest NGS genomic profiling techniques quickly.
Patient Consensus: Patients note that Israeli doctors often find treatment options or clinical trials missed by their local physicians. Many were surprised by how quickly they could arrange a video call to discuss rare mutations. Some Mentioned that sending pathology slides in advance is necessary to get the most out of the consultation.
Targeted therapy doctors in Israel use personalized testing to match treatments to a tumor's specific genetic profile. Leading specialists utilize advanced genomic sequencing and molecular profiling to identify actionable mutations. This precision approach is standard at JCI-accredited centers like Sourasky Medical Center and Assuta Medical Center.
Bookimed Expert Insight: Israel's leadership in genomic medicine is driven by specialists who also lead national research initiatives. For example, Dr. Ari Raphael at Sourasky Medical Center heads the Israeli National Genomic Medicine Initiative (PSIFAS). Patients often benefit from this integration, as doctors who participate in these national programs frequently serve as primary investigators for international clinical trials.
Patient Consensus: Patients note that while genetic testing is common, it is helpful to ask for comprehensive profiling early in the diagnosis. Many found that private facilities provide test results much faster than public options. They emphasize that's it's important to have a doctor who clearly explains how these test results change the treatment plan.
Patients seeking targeted therapy in Israel can expect seamless communication as English is the standard language for oncology consultations. Top specialists at facilities like Sourasky Medical Center undergo extensive training in the US, UK, and Europe, ensuring they are fluent in medical English.
Bookimed Expert Insight: A notable pattern among Israel's top oncologists is their dual role as researchers and clinicians. For instance, Dr. Ari Raphael and Dr. David Sarid lead national genomic initiatives and clinical trials, which necessitates daily professional-level English. Patients often find that these doctors explain complex molecular results more clearly than general practitioners because of their academic backgrounds.
Patient Consensus: Patients note that consultations are typically conducted entirely in English without any language barriers. They describe feeling relieved that physicians speak directly to them rather than relying on translation apps or intermediaries. Many were surprised at how easily they could discuss intricate treatment details and side effects during their appointments.